The Research We Cite, and What Each Study Can Support
Medically reviewed by
4 independent reviewers
Andrew Conrad Barile, PT, DPT
Doctor of Physical Therapy (DPT) | Licensed Physical Therapist (PT) | CEO and Founder, Xtreem Pulse LLC
Read bio
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC, the engineering company behind PureLift. He earned his Doctorate in Physical Therapy from Daemen College and is a licensed physical therapist.
He brings over two decades of clinical and entrepreneurial experience across physical therapy, craniosacral therapy and medical device innovation, built on a working knowledge of human anatomy and muscle physiology.
For PureLift LAB he reviews how current is delivered across all ten levels, from sub-sensory nanocurrent and skin-level microcurrent to motor-level EMS, and how the Infuse pass fits into the same ten-minute routine.
Bertica M. Rubio, M.D.
Board-Certified Physician, Dartmouth Medical School | Medical Director, Antiaging Regenerative Medicine Clinic
Read bio
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Doctor of Medicine from Dartmouth Medical School and completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, she specialises in age management medicine, regenerative medicine, wound healing and growth factor therapies, and her practice integrates evidence-based medical science with advanced aesthetic treatment.
For PureLift LAB she reviews articles for medical accuracy across the whole dial, from the gentle nanocurrent and microcurrent settings through to muscle-level EMS and the Infuse pass.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist | Head and Neck Surgeon | Fellow, American College of Surgeons | Mount Sinai
Read bio
Daniel Grinberg, MD, FACS is a board-certified otolaryngologist and head and neck surgeon at ENT and Allergy Associates in West Nyack, New York. He earned his medical degree from Columbia University College of Physicians and Surgeons.
He completed his otolaryngology residency at New York University Medical Center, serves as Assistant Clinical Professor at Mount Sinai School of Medicine, and is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
For PureLift LAB he brings a wider clinical lens, connecting at-home facial stimulation from microcurrent to EMS to the anatomy underneath, with the same rigour we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology
Read bio
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital.
He trained at the University of Hamburg, was a Max Planck Society Fellow at the Max Planck Institute for Heart and Lung Research, and held senior consultant posts at the Charite Universitatsmedizin Berlin before his appointment as Chair in 2016.
One of Europe's leading authorities on arteriogenesis, with over 150 peer-reviewed publications and US and EU patents, he reviews for PureLift LAB how the evidence on electrical stimulation is read and where its limits lie.
Share
This is the full list of research we cite across the site, with what each paper tested and what it can honestly support.
This article covers what actually decides the answer, such as:
- The facial studies
- The mechanism papers
- The modulation papers, including the one against us
- Why the list is short
- Why there is no PureLift trial
and many more!
The paper that disagrees with us on frequency modulation is in the list, because leaving it out would make the rest of the list worth less.
Key Points:
Everything below is category evidence under defined protocols, not product testing.
Four papers are facial; the rest are mechanism or limb-protocol work.
The strongest facial finding is an 18.6 percent increase in cheek muscle thickness over 12 weeks.
A study count is not an evidence base, which is why this page lists what each one says.
Check any of them yourself; every citation below carries a DOI or a PubMed identifier.
The facial studies
Kavanagh and colleagues, 2012, followed 108 women through 12 weeks of motor-level facial stimulation and measured an 18.6 percent increase in cheek muscle thickness (10.1111/jocd.12007). This is the single most relevant paper we cite and it supports the claim that motor-level facial stimulation increases facial muscle thickness over a season. It does not support any claim about a consumer device, a wrinkle outcome, or a timeline shorter than twelve weeks.
Chang and colleagues, 2020, ran a double-blind sham-controlled trial on facial stimulation (10.3390/ijerph17113783). The design is the important part: a sham group is the only way to separate an effect from expectation, and cosmetic outcomes are particularly vulnerable to expectation.
Kwak and colleagues, 2023, used a split-face design, treating one side and using the other as the control (10.52660/jksc.2023.29.6.1505). Split-face removes the person as a variable, which is a genuine strength.
Lee and colleagues, 2007, ran a split-face LED study (PMID 17566756). It is relevant to GLOW's light and not to the current.
The mechanism papers
Ward, 2009, sets out the three current thresholds that separate sub-sensory, sensory and motor stimulation (PMID 19095805). This is the paper behind every statement we make about where the motor threshold sits and why microcurrent devices cannot contract a muscle.
Prausnitz and colleagues, 1993, describe electroporation, the mechanism behind Infusion (10.1073/pnas.90.22.10504). It is foundational work on the principle rather than a study of a cosmetic device.
Saniee and colleagues studied low-level stimulation effects (10.29252/jmj.10.2.9), which is the kind of work underlying the nanocurrent and microcurrent bands. Most of that literature was run at microamp rather than nanoamp levels, which is a limitation we note wherever we cite it.
The modulation papers, including the one against us
Downey and colleagues, 2011, found that varying frequency extended a defined performance endpoint against constant frequency in a neuromuscular protocol (PMID 21996798). This is the design rationale for PDM and it is a limb protocol measuring performance rather than appearance.
Papaiordanidou and colleagues, 2014, report a case where frequency modulation did not deliver the expected benefit (10.1371/journal.pone.0084740). We cite it on every page where we cite Downey, because a literature with mixed findings is what this one is and presenting only the supportive half would be selection rather than evidence.
Maffiuletti and colleagues, 2018, make the point that a dial setting is not the same as the tension actually produced in the muscle (PMID 29233625). That is why comparing two brands by their level numbers is meaningless.
Why the list is short
A long citation list is easy to produce and tells you very little, since papers can be added that are tangential, superseded, or do not say what the sentence citing them implies.
What matters is whether each paper tested something close to the claim it is supporting, and that is why this page describes each one rather than counting them.
If another brand shows you a number of sources, ask which one supports the specific claim you are reading, and expect that to be a harder question than it sounds.
Why there is no PureLift trial
We have not run a clinical trial on our own devices. A properly designed one, sham-controlled, adequately powered and independently conducted, is expensive and slow, and almost nobody in the consumer beauty device market has run one.
That is an explanation rather than an excuse, and the consequence is that every study above is category evidence about what facial electrical stimulation can do under defined conditions, not evidence about what our product will do to your face.
What is specific to our devices is the specification, and that is checkable: 7 mA at 500 ohms for Face and Pro with a 4 microsecond pulse, 7.7 mA for Pro Edition, 9 mA for Pro Plus and GLOW, cleared under K190269, K230506, K221443 and K243587, made in Japan in an ISO 13485 facility.
How to use this page
When you read a claim of ours anywhere on this site, find the study behind it here and check whether the paper tested something close to the claim.
Do the same to every other brand in this category, and treat the completeness of the answer as part of the answer.
For the method, see how to read a facial device study.